76
Participants
Start Date
November 14, 2024
Primary Completion Date
November 15, 2026
Study Completion Date
November 15, 2026
Irinotecan Liposome
②LV: 400mg/m2, intravenous infusion, Q2W, d1; ③5-FU: 2400 mg/m2, continuous intravenous infusion, Q2W, d1-2;
Capecitabine
① Capecitabine, 1250mg/m2 orally, bid, Q3W, d1-14;
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
Zhejiang Cancer Hospital, Hangzhou
Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine, Hangzhou
Fujian Provincial Hospital, Fuzhou
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou
Zhejiang Cancer Hospital
OTHER
RenJi Hospital
OTHER
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Fujian Provincial Hospital
OTHER
Ningbo No. 1 Hospital
OTHER
Shaoxing People's Hospital
OTHER
Southern Medical University, China
OTHER
First Affiliated Hospital, Sun Yat-Sen University
OTHER
Sir Run Run Shaw Hospital
OTHER